← All indications
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
Subtype terms (1)
More specific conditions that are subtypes of Acute Lung Injury in the MeSH hierarchy.
- Transfusion-Related Acute Lung Injury
4 drugs approved
Drugs by status
Approved for this indication (1)
Phase 4 trials (9)
Phase 3 trials (10)
Phase 2 trials (35)
- phenylephrine
- alt-836
- acetylcysteine
- maraviroc
- axv-128
- norepinephrine
- etanercept
- gsk2586881
- ic14
- baricitinib
- ganciclovir
- vitamin c
- perfluorocarbon
- pirfenidone
- lactose
- prochlorperazine
- epinephrine
- dilmapimod
- acetylsalicylic acid
- endotoxin
- furosemide
- umbilical cord mesenchymal stem cells
- decidual stromal cells
- menstrual blood stem cells
- dobutamine
- vasopressin
- peginterferon beta-1a
- unfractionated heparin
- fish oil
- voxelotor
- +5 more
Organizations
Organization Involved with Phase 4 Indications (23)
- National Heart, Lung, and Blood Institute (NHLBI)
- Huazhong University of Science and Technology
- Aarhus University
- University of Arizona
- Hospital General Universitario Gregorio Marañon
- I.M. Sechenov First Moscow State Medical University
- Mahidol University
- Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy
- Nanjing Medical University
- Radboud University
- University of Valencia
- Aalborg University
- Istanbul University
- Southeast University
- Mario Negri Institute
- Aix-University of Marseille
- B. Braun
- Ono Pharmaceuticals
- Consorcio Centro de Investigación Biomédica en Red, M.P.
- University Clermont Auvergne
- Li Ka Shing Knowledge Institute
- Universidad Carlos III Madrid
- Frederick Health
Organization Involved with Phase 3 Indications (103)
- Asklepion
- Ache Laboratorios Farmaceuticos S.A.
- Alexion
- Chimerix
- Faron Pharmaceuticals Ltd
- Laboratoire français de Fractionnement et de Biotechnologies
- Mallinckrodt
- NeuroRx, Inc.
- Pneuma Pharmaceuticals Incorporated
- Sage Therapeutics
- Boehringer Ingelheim
- University of Roma La Sapienza
- Shahid Beheshti University of Medical Sciences
- University of Pennsylvania
- University of Manitoba
- University of Pittsburgh
- Baylor University
- Centre Chirurgical Marie Lannelongue
- Centre Hospitalier St Anne
- Centre Jean Perrin
- University of London
- Harvard University
- Duke University
- Federal University of Juiz de Fora
- Emory University
- University of Washington
- Hôpital Raymond Poincaré
- Hospital do Coracao
- Hospital Sirio-Libanes
- Johns Hopkins University
- +73 more
Organization Involved with Phase 2 Indications (128)
- Actelion
- Theravance
- United Therapeutics
- Debiopharm
- Eli Lilly
- Genentech
- Akebia Therapeutics
- Aerpio Therapeutics
- Aevi Genomic Medicine
- Athersys, Inc
- Bayer
- Biocon Limited
- Cell Therapy Catapult
- Cellular Biomedicine Group Ltd.
- Chiesi
- GlaxoSmithKline
- Hope Pharmaceuticals
- Healios K.K.
- Implicit Bioscience
- PhaseBio Pharmaceuticals Inc.
- S-Evans Biosciences Co.,Ltd.
- Techpool Bio-Pharma Co., Ltd.
- Windtree Therapeutics
- Apellis Pharmaceuticals, Inc.
- Apeptico Forschung und Entwicklung GmbH
- Cynata Therapeutics Limited
- Iltoo Pharma
- National Institutes of Health (NIH)
- National Cancer Center, Korea
- National Center for Research Resources (NCRR)
- +98 more
Organization Involved with Phase 1 Indications (29)
- Jazz Pharmaceuticals
- Tanox
- Parexel
- Agenus Inc.
- Savara Inc.
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Medical Center of Central Georgia
- Northern State Medical University
- Shaoxing Second Hospital
- University of Kentucky
- University of Oklahoma
- University of Ottawa
- University of South Carolina
- University of Toronto
- Stony Brook University
- State University of New York
- Uppsala University
- Celerion
- Sun Yat-Sen University
- Methodist Cancer Center, Houston, Texas
- Northern Norway Regional Health Authority
- Stem Cell Network
- Meridigen Biotech Co., Ltd.
- Exvastat Ltd.
- Viela Bio
- Instituto de Medicina Regenerativa
- MiNK Therapeutics
- ReAlta Life Sciences, Inc.
Organization Involved with Other Experimental Indications (11)